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Abstract (248 / 250 words) 
Objectives: In the national newborn screening programme for CF in Switzerland, we 
compared the performance of two sweat test methods, by investigating the feasibility and 
diagnostic performance of the Macroduct  collection method (with chloride mesurement) and 
Nanoduct test (measuring conductivity) for diagnosing CF. 
Study-design: We included all newborns with a positive screening result between 2011 and 
2015 who were referred to a CF-centre for sweat testing. In the CF-centre, a Macroduct and 
Nanoduct sweat test were performed simultaneously. If sweat test results were positive or 
borderline, a DNA analysis was performed. Final diagnosis was based on genetic mutations.   
Results: Over five years, 445 children were screened positive and in 413 (114 with CF) at 
least one sweat test was performed (median age at first test, 22 days); both tests were 
performed in 371 children. A sweat test result was more often available with the Nanoduct 
compared to the Macroduct (79% vs. 60%, p<0.001). The Nanoduct was equally sensitive as 
the Macroduct in identifying newborns with CF (sensitivity 98% vs. 99%) but less specific 
(specificity 79% vs. 93%; p-value comparing ROC curves=0.033).  
Conclusions: This national multicentre study revealed high failure rates for Macroduct and 
Nanoduct in newborns in real life practice. While this needs to be addressed, our results 
suggested that performing the Nanoduct in addition to the Macroduct might speed up the 
diagnostic process because it more often yields valid results with comparable diagnostic 
performance. The addition of the Nanoduct sweat test can therefore help to reduce the 
stressful time of uncertainty for parents and to start appropriate treatment earlier. 
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Introduction 
The widespread implementation of newborn screening (NBS) for cystic fibrosis (CF) has 
changed the diagnostic paradigm: in contrast to patients who are diagnosed because of 
symptoms healthy newborns are referred for diagnostic testing after a positive screening 
result.1 Apart from some newborns with meconium ileus, these children have no (or only 
minimal) clinical manifestation of the disease, making sweat tests the main diagnostic tool to 
discriminate between children with and without CF.2-4 Sweat collection in these newborns is 
challenging and must be performed according to the current guidelines.5-7 The 
recommendations of the Cystic Fibrosis Foundation (CFF) say that the proportion of 
unsuccessful sweat tests in infants should be ≤10%.5,8 In real life, it can vary between 0 to 
40% during the first three months of life.8-12 
Determining sweat chloride concentration is the current standard criterion for the 
diagnosis of CF.3,5 This is nowadays usually done with the Macroduct collection system that 
was introduced in 1986 and needs 15µl of sweat.13-16 Measuring conductivity using the Sweat-
Chek analyser has been suggested to be as effective as chloride determination in 
discriminating healthy children from those with CF.13,17-19 Nanoduct is a newer sweat 
conductivity analysis system that was specially developed for newborns because it requires 
only 3–5µl of sweat and measures conductivity in situ.20 However, only a few studies have 
assessed its ability to discriminate between CF patients and healthy children.21-25 Neither 
American nor European guidelines have yet accepted sweat conductivity as diagnostic critera 
for CF.5,6,15 
In Switzerland, CF-NBS was introduced in 2011.26-30 With the implementation of the 
programme, the Swiss Federal Office of Public Health requested a close evaluation of the 
programme including the use and comparison of two different sweat test systems 
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(Macroduct collection system with chloride measurement and Nanoduct analysis system) 
for the diagnostic evaluation in newborns with a positive CF-NBS result. We therefore aimed 
to 1) compare the feasibility of the two tests in infants (overall, and according to age and 
weight),  2) compare the diagnostic performance of the tests in identifying infants with CF, 
and, 3) investigate whether the diagnostic performance of the Macroduct alone could be 
improved by also taking the Nanoduct result into account.  
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Materials and methods 
The Swiss NBS programme consists of two parts: the screening part in the NBS laboratory, 
and, for screen positive infants, the diagnostic evaluation in the CF-centres.28 The comparison 
of the two sweat test systems within the NBS was requested by the Swiss Federal Office of 
Public Health (FOPH) when starting the CF-NBS in 2011 and approved by the Swiss National 
Ethics Committee. 
The Swiss CF-NBS 
The Swiss CF-NBS comprises the measurement of immunoreactive trypsinogen (IRT) in a 
heel prick test (Guthrie card) on the 4th day of life of all newborns in Switzerland.26-30  If the 
IRT is above the specified cut-off (99.2 percentile), the most common CFTR mutations 
(initially 7, since 2013: 18) are sought. If at least one mutation is found, the newborn is screen 
positive. If no mutation is found, as a safety net, a second IRT is performed if the first IRT 
was ≥60 ng/ml. If this IRT is again above the same cut-off the newborn is also screen 
positive.  
This study includes all newborns screened positive and referred to one of eight paediatric CF-
centres for diagnostic evaluation in the Swiss CF-NBS between January/2011 and 
December/2015 (E-figure 1).  
Diagnostic evaluation in the CF-centres 
The Swiss CF-NBS uses two different sweat tests, simultaneously, one at each arm: the 
Macroduct sweat collection system (Wescor Inc., Logan, Utah, USA) followed by a 
coulometric determination of chloride in the laboratory and the Nanoduct sweat analysis 
system (Wescor) which measures conductivity in situ.21 If the Macroduct and Nanoduct are 
positive or intermediate (or the infant had two mutations in the screening and insufficient 
sweat was collected or both sweat tests are negative), CFTR mutation analysis is performed 
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(E-figure 1). If both sweat tests are negative, the infant is considered a healthy carrier. If 
Macroduct and Nanoduct differ, the result of the Macroduct is used as decision criteria. If no 
Macroduct result is available, decisions on further evaluations are based on the Nanoduct. If 
no sweat test result is available, decision on further evaluation is based on the screening 
results and fecal elastase.30 In any case, Macroduct sweat tests are repeated until a chloride 
result is obtained.  
1. Macroduct sweat collection system and chloride determination 
The Macroduct test was performed according to current guidelines; a pilocarpine 
iontophoretic stimulation was followed by sweat collection with the Macroduct collector 
system.14,17 Sweat chloride concentration (in mmol/L) was measured by coulometry in all 8 
paediatric CF centres (most used Chloridometer FGKO, Kreienbaum Neosience GmbH, 
40674 Langenfeld, Germany). Sweat chloride of ≥60 mmol/L was considered diagnostic for 
CF, values from 30-59 mmol/L as intermediate.3  
2. Nanoduct sweat test analysis system 
The Nanoduct system induces and analyses sweat in situ while attached to the child.20,21 
Conductivity is expressed as mmol/l eq NaCl. This is not equal to a quantitative chloride 
measurement and is approximately 15-23 mmol/L higher than the sweat chloride because of 
additional anions such as lactate and bicarbonate.17,18,21 A value ≥80 mmol/L was considered 
consistent with the diagnosis of CF, values from 50-79 mmol/L as intermediate.13,17,21,23 In 
healthy newborns at the age of 3-4 weeks, mean conductivity was 36 mmol/L with a range of 
12-64.31 
3. CFTR mutation analysis  
Genomic DNA was extracted from peripheral blood cells. In a first step, the laboratory tested 
for 50 mutations using a Multiplex-PCR and Amplification Refractory Mutation System 
(ARMS™; ELUCIGENE® CFEU2v1 Kit).26,27 When fewer than 2 mutations were detected, 
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the entire coding sequence of the CFTR gene was screened, including intron/exon boundaries, 
promoter region, and tests for deletions and duplications. 
Definition of final diagnosis 
For the purpose of this study, we defined the final diagnosis (the “criterion standard”) solely 
on the genetic mutations according to the CFTR2 (www.cftr2.org) or CFTR1 
(http://www.genet.sickkids.on.ca/app) database or the American College of Medical Genetics 
and Genomics (ACMG)-Criteria32: a CF diagnosis was made if two CF-causing mutations 
were present, a Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) if two 
CFTR mutations were present and at least one of them was not CF-causing (all newborns in 
our study that received the full genetic workup had two mutations identified).33 We then 
assessed the diagnostic performance of the two sweat tests by comparing them to this 
diagnostic criterion standard.  
To calculate the true negative and false negative sweat test results we needed to be sure 
that none of the children with a negative sweat test result had in fact CF. To ensure this, all 
children (born 2011-2015) diagnosed with CF based on clinical symptoms (outside the CF-
NBS) are reported to the central database by the clinicians of the CF-centres.  
Data collection 
All positively screened children are registered in a central database. Clinical data, diagnostic 
test results and genetic mutations are reported by the physicians. This analysis used the 
following data: date of birth, sex, birth institution, birth weight, gestational age, CF-centre, 
final diagnosis, CFTR mutations and sweat test results including number of tests attempted, 
number of successful tests, age and weight at each test, and chloride and conductivity results.   
Statistical analysis 
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We included all sweat tests performed at an age ≤90 days. To assess the feasibility of the 
tests, we used the first attempted sweat test. For the other analyses we used the first successful 
sweat test result (i.e. the first sweat test with a usable result). Macroduct and Nanoduct results 
are described separately. A sweat test was considered successful if judged as such by the 
performing clinician/technician and a sufficient amount of sweat was collected (quantity not 
successful (QNS) = <15µl for Macroduct and <1g/m2/min for Nanoduct (shown on the 
display)).  
We compared the proportion of successful tests (feasibility) at first attempt, overall and 
stratified by child age and weight. Using logistic regression we determined whether the 
child’s age or weight was predictive for the sweat test success.  
We calculated the following screening parameters for the Macroduct and Nanoduct to 
compare the diagnostic performance of the tests in identifying children with and without CF: 
sensitivity and specificity, false negative rate, false positive rate, positive predictive value, 
and negative predictive value. We calculated these parameters for a intermediate chloride cut-
off of 30 mmol/L (Macroduct) and a conductivity cut-off of 50 mmol/L (Nanoduct), the 
defined cut-offs of the Swiss CF-NBS, which determine whether a child is further evaluated 
with genetic analysis or released as healthy28. We compared the areas under the receiver 
operating characteristic (ROC) curves to test for a significant difference of the sensitivity and 
specificity between the Macroduct and Nanoduct sweat test. Further, for children with both 
Macroduct and Nanoduct data, we plotted chloride versus conductivity in relation to the final 
diagnosis, and did Bland-Altman and Bias plots. These two plots allow the identification of 
any systematic differences between the two sweat test systems across the range of 
chloride/conductivity levels.  
We investigated whether the diagnostic performance of the Macroduct alone could be 
improved by taking into account the Nanoduct result. For this, we considered two scenarios: 
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following up all children who 1) had either a positive Macroduct (chloride ≥60 mmol/L) or 
Nanoduct (conductivity ≥80 mmol/L), or 2) had either a intermediate Macroduct (chloride 
≥30 mmol/L) or Nanoduct (conductivity ≥50 mmol/L).  
All analyses were performed in STATA, version 14 (StataCorp LP, College Station, 
Texas, USA) and a p-value of <0.05 was considered statistically significant. 
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Results 
Characteristics of study population 
Over five years, 445 infants were screened positive and referred to a CF-centre for diagnostics 
(E-figure 2). Among these, 432 came to the CF-centre and 413 (50% boys, 91% born in a 
hospital, Table 1) had at least one sweat test performed by age ≤90 days. Both tests were 
attempted in 371 infants, and for 229 both yielded a usuable result. CF was diagnosed in 114 
infants (28% of 413), 16 (4%) had an inconclusive diagnosis (CFSPID), and 283 (69%) were 
classified as healthy (Table 1). Overall, we performed 924 sweat tests: 458 Macroduct tests in 
382 infants and 466 Nanoduct tests in 402. On average, infants were 22 days old (range 4–90 
days) at the time of the first sweat test and weighed 3745g (range 2350–6830g).  
Feasibility of Macroduct and Nanoduct  
Overall, a Macroduct test was attempted in 382 infants and successful in 229 (60%, Table 2). 
Proportions of successful tests ranged from 47% to 83% in the CF-centres (Figure 1A). A 
Nanoduct test was attempted in 402 infants and successful in 317 (79%, range between 
centres, 57%–91%). The main reason for unsuccessful tests in both systems was an 
insufficient amount of sweat. The Macroduct failed significantly more often than the 
Nanoduct. This was true overall and within weight categories (all p<0.001; Figure 1B). 
Among the 149 infants (40%) with unsuccessful Macroduct tests at first attempt, 89 had a 
valid Nanoduct test result. Of these, 29 had CF and were correctly identified by the Nanoduct 
with conductivity ≥80 mmol/L. Among the 78 infants (21%) with an unsuccessful Nanoduct 
test at first attempt, 18 had successful Macroduct results. Of these, 5 had CF and were 
correctly identified by the Macroduct with chloride ≥60 mmol/L.  
The proportion of successful tests increased with increasing weight (p<0.001 for both 
tests; Figure 1B).  Age was associated with test success in the univariable analysis but only 
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weight remained an independent predictor in the adjusted model with an odds ratio (OR) of 
3.0 (95% confidence interval [CI] 1.9–4.7) per kg increase in weight for the Macroduct, and 
an OR=3.5 (95% CI 2.1–6.0) per kg for the Nanoduct. 
Diagnostic performance of Macroduct compared to Nanoduct  
Overall, both sweat test systems discriminated well between infants with and without CF (E-
table 1). However, within the CF patients there was one infant with a normal chloride level 
and two infants with normal conductivity levels; all three had 2 CF-causing mutations and 
were pancreatic insufficient. One healthy infant had a conductivity ≥80 mmol/L.  
The clinical sensitivity of the Macroduct test system (for the intermediate cut-off of 
chloride ≥30) was 99%, and it was 98% for the Nanoduct system (for the intermediate cut-off 
of conductivity ≥50; Table 3); the clinical specificity of each was 93% and 79%, respectively 
(p-value comparing ROC curves=0.033). The positive predictive values of Macroduct and 
Nanoduct were 84% and 62%, respectively.  
The scatterplot comparing chloride and conductivity results for the same infant (n=229) 
resulted in an estimated linear regression line with an intercept of 29.4 mmol/L and a slope of 
0.78 (95% CI 0.73–0.83, Figure 2). The Bland-Altman plot showed that conductivity was on 
average 22.0 mmol/L higher than the chloride concentration. However, the difference 
decreased with increasing mean chloride/conductivity levels with a slope of -0.13 for the 
estimated linear regression line (95%CI -0.19 – -0.07; Figure 3). The same was true for the 
Bias plot comparing the difference between conductivity and chloride to the chloride level 
(slope of estimated linear regression -0.22 [95%CI -0.27 – -0.16]; E-figure 3). 
Diagnostic performance of Macroduct and Nanoduct together  
We investigated whether the diagnostic performance of the current criterion standard 
Macroduct could be improved by the Nanoduct results (Table 3). First of all, more infants had 
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a valid test result when considering both tests (n=371, compared to 258 for only the 
Macroduct). Had we followed-up every child with a positive Macroduct or Nanoduct test 
result (Macroduct CF positive cut-off of chloride ≥60 or Nanoduct CF positive cut-off of 
conductivity ≥80), the sensitivity of the sweat test would have decreased from 99% for the 
Macroduct alone to 92%. However, with only 1 false positive child the specificity would have 
improved to almost 100% (compared to 93% of the Macroduct alone). On the other hand, had 
we had followed-up every child with a intermediate Macroduct or Nanoduct (Macroduct 
intermediate cut-off of chloride ≥30 or Nanoduct intermediate cut-off of conductivity ≥50) the 
sensitivity would have increased to 99% (compared to 98.5% for the Macroduct alone), but so 
would the number of false positive test results (to yield a specificity of 78%). 
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Discussion 
This study, done in a real-life context of a national newborn screening programme found that 
only 60% of Macroduct tests were successful at first attempt, with considerable variation 
between centres. The Nanoduct was more often successful (79%) and as sensitive as the 
Macroduct in identifying newborns with CF (sensitivity 98% vs. 99%, respectively), but less 
specific (specificity 79% vs. 93%). Considering the Nanoduct result in addition to the 
Macroduct alone could not improve “the Swiss” sensitivity/specificity of the diagnostics, 
however, 29 children with an unsuccessful Macroduct at first attempt could be correctly 
identified as having a CF on the basis of genotype analysis, directed by a positive Nanoduct 
result ≥80 mmol/L. 
Strengths and limitations 
This is a prospective, population-based, long-term study that closely evaluated the Swiss CF-
NBS programme since its beginning in January 2011. The study reflects the daily clinical 
practice including the eight Swiss paediatric CF-centres and other relevant partners (national 
NBS and genetic laboratories). Within the study, we collect a variety of variables in a central 
database that included a large cohort of 432 children. All centres have indicated that they have 
performed the sweat tests according to current guidelines, but checking all procedures of each 
centre during a sweat test symposium in 2016 (after the study period) revealed variations in 
procedure and materials between CF-centres, which reflects findings of a recent European 
survey of real life practice of sweat testing.34 
Comparison with other studies  
The collection of a sufficient amount of sweat to measure chloride in infants is challenging, 
and studies report between 0% and 40% invalid Macroduct tests in children <3 months of 
age.8-11 In our study test success increased with weight, and was higher for Nanoduct than for 
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Macroduct, which is in line with our previous single-centre21 and multicentre22 studies, and 
studies from other groups.24,35 However, the proportion of unsucessful tests, 40% for the 
Macroduct (range between centres 17–53%) and 21% for the Nanoduct (range between 
centres 9–43%), was higher than in our previous and international studies. In our previous 
studies we had 15% and 18% of unsucessfull Macroduct tests and 3% and 6% of unsuccessful 
Nanoduct tests. In the Dutch study by Vernooij-van Langen et al., the proportion of 
unsucessful results was 7.5% for Nanoduct, and 22% for Macroduct.24 One reason for these 
differences might be that he Swiss CF-NBS assesses newborns earlier and with lower weight 
than other studies. Furthermore we do each test only once (Macroduct on one arm and 
Nanoduct on the other arm) whereas others perform the same test twice in parallel. Lastly, 
ours was a nationwide study including all CF-centres with differently experienced staff and 
different methods.  
For our chloride cut-off of 30 mmol/L, we had a clinical sensitivity of 99%, specificity 
of 93%, and positive predictive value (PPV) of 84%. The only study using a similar cut-off 
(34 mmol) was the Polish study by Sands and colleagues including 487 infants (45 with CF) 
over 3 years (2006–2009).23 For their cut-off, they reported a Macroduct sensitivity of 100%, 
a specificity of 98%, and a PPV of 80%. For our conductivity cut-off of 50 mmol/L, we 
calculated a sensitivity of 98%, specificity of 79%, and a PPV of 62%. The study by Sands et 
al. with the same cut-off, reported a Nanoduct sensitivity of 100%, a specificity of 98% and a 
PPV of 79%. However, these two studies are difficult to compare. For the current analysis, we 
have explicitly used the CFTR genotype interpreted by the CFTR2/CFTR1 databases and the 
ACMG criteria as standard for the final diagnosis. Only this approach allows calculating the 
independent performance of the sweat test in discriminating CF patients from healthy 
individuals. The Polish study by Sands has, however, included the sweat test result in addition 
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to genetic mutation in the definition of their final diagnosis which will increase the sensitivity 
and specificity of the test.36  
Interpretation of results and clinical implications 
The proportion of unsuccessful sweat tests in the Swiss CF-NBS is too high and we are 
striving to improve this. Small differences in the conduct of the sweat test across centres 
might be a reason for the high proportion of unsuccessful sweat tests. As a result of this study, 
we have tried to find out reasons for the high proportion of unsuccessful sweat tests and found 
out that one centre did not properly clean the skin before the sweat test, and another centre has 
sent the Macroduct collector to the laboratory without proper sealing. A few centres have 
collected the sweat for more than 30 minutes, and one centre had a not properly working 
induction apparatus. This emphasizes the importance to pay attention to the technical details 
of sweat testing and train staff to exactly follow the official guidelines when performing sweat 
tests.5-7 Because of these results, the PI of the study [JB] now visited different CF-centres in 
Europe with better sweat test results to identify differences between their and the Swiss 
procedures. We organized a workshop for all the Swiss paediatric CF centres to bring this 
expertise to Switzerland and discuss the procedures in Swiss centres, particularly in centres 
with a low proportion of successful tests. We will closely observe whether this initiative will 
improve performance or further actions need to be taken, for example reducing the number of 
national diagnostic centres so that the staff is more experienced. For a small country like 
Switzerland (8.2 million inhabitants), eight CF-centres are rather many resulting in only a few 
newborns tested per year in the smaller centres. 
Overall, we had three false negative sweat test results, one with Macroduct and two with 
Nanoduct. A chloride measurement of 10 mmol/L in a child with CF and pancreatic 
insufficient is physiologically not possible and must be a technical failure (e.g. incorrect 
cleaning of the skin before sweat collection or dilution in the laboratory).37 The two Nanoduct 
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results of 49 and 47 mmol/L in children with CF are most likely due to a technical problem as 
the conductivity level should be higher than the according chloride value of these children (77 
and 89 mmol/L, respectively). We could not determine the reason for the only false positive 
Nanoduct result of 80 mmol/L in a healthy carrier.  
All studies comparing the Nanoduct and Macroduct sweat test systems (including ours), 
found that the Nanoduct yields a higher proportion of successful tests in newborns.23,24 We 
found that a Nanoduct result was obtained in 89 infants in whom no Macroduct result could 
be obtained. Among these, 29 had CF and were correctly identified with conductivity ≥80 
mmol/L. Thanks to the available Nanoduct result, a presumptive diagnosis could be made in 
these children and appropriate CF treatment was started.38 This is important to reduce the 
stressful time of uncertainty in parents awaiting a final diagnosis.29 In the Swiss NBS, at the 
first visit in the CF-centre we therefore recommend simultaneously performing a Macroduct 
and a Nanoduct sweat test to increase the probability of at least one successful sweat test 
result. In any case, it is necessary at some stage to confirm the diagnosis with a sweat chloride 
measurement. This is important because sweat chloride is a main outcome in studies with 
CFTR-modulators and the only diagnostic measure for CF accepted by current American and 
European guidelines.5,6,39 However, we cannot say whether performing Macroduct and 
Nanoduct simultaneously, one at each arm, yields more successful tests than performing two 
Macroducts simultaneously. This needs to be investigated in a randomized controlled trial.  
We also looked at whether we could improve the clinical sensitivity and specificity of 
the current criterion standard Macroduct by taking into account the results of the Nanoduct 
test as well. We found that this approach could reduce the number of false positives, but only 
at the cost of a reduced sensitivity.  
Conclusion 
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The Nanoduct more often yields a successful result due to its lower sweat weight requirement. 
In the presence of high Macroduct failure rates, we therefore suggest performing the 
Nanoduct sweat test in addition to the Macroduct for the diagnostic evaluation within the CF-
NBS. This is especially relevant in very young newborns with a low weight, where there is a 
high probability of not getting enough sweat for a chloride measurement. The Nanoduct can 
add to the diagnostic matrix when sweat collection for the Macroduct is insufficient. This can 
hasten the diagnosis, which is important to start appropriate treatment as early as possible and 
reduce the stressful time of uncertainty for parents.  
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Table 1. Characteristics of subjects included in the study (N=413). 
 n %
a 
Child’s demographic characteristics   
Year of birth   
 2011 80 19.4 
 2012 77 18.6 
 2013 83 20.1 
 2014 101 24.5 
 2015 72 17.4 
Sex 
  
 
Male  206 49.4
 
Female 204 49.9 
Missing 3 0.8 
Clinical characteristics   
Birth institution   
 Hospital 373 90.3 
 Birthing centre 3 0.7 
 Home 25 6.1 
 Other 9 2.2 
 Missing 3 0.7 
Final diagnosis   
 No CF 283 68.5 
 CF 114 27.6 
 CFSPID 16 3.9 
Sweat tests   
Number of Macroduct tests performed   
 No test 31 7.5 
 1 test 315 76.3 
 2 tests 60 14.5 
 3 tests 5 1.2 
 4 tests 2 0.5 
Number of Nanoduct tests performed   
 No test 11 2.7 
 1 test 346 83.8 
 2 tests 50 12.1 
 3 tests 4 1.0 
 4 tests 2 0.5 
    
Continuous variables   
  Median Range 
 Gestational age (w) 39 27-49 
 Birth weight (g) 3280 480-4660 
 Age at the first visit in the CF-centre (d) 22 4-90 
 Weight at the first visit in the CF-centre (g) 3745 2350-6830 
NOTE: Percentages are based upon available data for each variable.  
Abbreviations: CF, cystic fibrosis; CFSPID, cystic fibrosis screen positive inconclusive 
diagnosis; d, days; g, grams; n, number; w, weeks. 
a Column percentages.  
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Table 2. Proportion of successful sweat tests at the first attempt and mean weight at test for 
Macroduct and Nanoduct 
 Macroduct 
 
Nanoduct 
 
p-valuea 
Proportion of successful sweat tests 
 
  
  
 N % (95% CI)  N % (95% CI)   
All tests attempted 382   402    
        
Tests valid 229 60 (55 - 65)  317 79 (75 - 83)  n.a.b 
Reason tests not valid 
  Not enough sweat 
  Technical problems 
  Reason unknown 
136 
1 
16 
89 
1 
10 
 
67 
4 
14 
79 
5 
16 
  
n.a.b 
        
Test pairs  371   371    
        
Tests valid 222 60 (55 - 65)  293 79 (75 - 83)  <0.001 
Abbreviations: CF, cystic fibrosis; CI, confidence interval; n.a., not applicable. 
a p-value from chi square statistics and t-test comparing the Macroduct and Nanoduct. 
b p-value not applicable because the Macroduct and Nanoduct results cover different groups of 
children (depending whether or not the respective test was attempted). 
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Table 3. Diagnostic performance for CFa of  the Macroduct and Nanoduct sweat test and a combination of both tests. 
 True positives 
False 
negatives 
False 
positives 
True 
negatives Total tests Sensitivity Specificity PPV NPV 
MACRODUCT 
(intermediate cut-off 
chloride 30-59)b 
67 1 13 177 258c 99% 93% 84% 99% 
NANODUCT (intermediate 
cut-off conductivity 50-79)b 87 2 54 199 342
d 98% 79% 62% 99% 
MACRODUCT CF positive 
cut-off chloride ≥60 OR 
NANODUCT CF positive 
cut-off conductivity ≥80 
89 8 1 273 371e 92% 100% 99% 97% 
MACRODUCT 
intermediate cut-off 
chloride ≥30 OR 
NANODUCT intermediate 
cut-off conductivity ≥50 
96 1 61 213 371e 99% 78% 61% 100% 
Abbreviations: CF, cystic fibrosis; NPV, negative predictive value; PPV, positive predictive value. 
a The final diagnosis was based on the CFTR2 database (http://www.cftr2.org/) at Johns Hopkins University, CFTR1 
(http://www.genet.sickkids.on.ca/app) database at the Hospital for Sick Children in Toronto or the American College of Medical Genetics and 
Genomics (ACMG)-Criteria. 
b Macroduct chloride of 30mmol/L and Nanoduct conductivity of 50mmol/L are the relevant cut-offs in the Swiss CF-NBS whether a child will 
be further followed up with genetic analysis and assessment of pancreatic function, or declared as healthy. 
c Overall, we had 262 valid Macroduct tests, but only 258 with information on chloride. For four infants, unfortunately only the osmolarity was 
provided from the Macroduct sweat test instead of the chloride results.   
d Overall, we had 342 valid Nanoduct tests and conductivity results. 
e Overall, 371 children had at least one valid sweat test result. 
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